• Ensuring 340B Integrity

    Ghalib Abbasi
    Journal Citation: Pharmacy Purchasing & Products July 2018 – Vol. 15 No. 7 – p26

    In the July edition of Pharmacy Purchasing & Products, Ghalib Abbasi, PharmD, MS, MBA, shares his 340B expertise in this Q&A session.

    Read the full article here

  • Visante Insider – June 2018

    In this edition of the Visante Insider:

    Introducing the Business of Pharmacy™ Forum
    What hospital executives need to know to protect their 340B Programs
    On the Road to USP 800 Compliance - Section 10
    Recruiting  - VP Pharmacy at Baptist Health
  • Top leaders in pharmacy gather to address major issues facing IDNs in 2018

    Journal Citation: Becker’s Hospital Review, June 5, 2018

    Written by James Jorgenson, RPh, MS, FASHP, Chief Executive Officer, Visante, Inc., Lynn Eschenbacher, PharmD, MBA, FASHP, Chief Pharmacy Officer, The Resource Group, Cedric Terrell, PharmD, MHA, Senior Vice President, Pharmacy Services, Novant Health

    No question that healthcare today is experiencing challenges and a pace of change never before seen. Patient access and service demands, rising costs, decreasing reimbursement and quality/safety improvement demands are all converging to create a “perfect storm” for healthcare leaders. Healthcare leaders might be wise in taking a page from one of America’s most successful investors, Warren Buffet. Mr. Buffet believes in long term value investing because he understands the power of exponential growth. Companies with sustainable profits can pay and grow their dividends. He regards down markets as an opportunity to buy good companies at reasonable prices.

    Read the full article here

  • Tools of the trade: Creativity, innovation, influence, and advocacy

    James Jorgenson
    Journal Citation: Am J Health-Syst Pharm. 2018; 75:785-94

    In this article published in the June edition of the American Journal of Health-System Pharmacy, James Jorgenson, B.S.Pharm., M.S., FASHP, Visante Inc. & Visante Ltd., shares his John W. Webb lecture.

  • Visante Insider – May 2018

    In this edition of the Visante Insider:

    340B regulatory and legislative update for May 2018
    Insights into Edaravone - first new drug to treat ALS in 25 years
    PCMA study shows benefits of E-prescribing of controlled substances
  • Your 340B program is NOT just a pharmacy endeavor: What hospital executives need to know to protect their programs

    Journal Citation: Becker’s Hospital Review, May 18, 2018

    Written by Gregory Strohs, RPh, MBA, Corporate Director of Pharmacy, Adventist Health System & James Jorgenson, RPH, MS FASHP, Chief Executive Officer, Visante Inc.

    The 340B program presents covered entities with very important financial support to assist with the extension of care to the most vulnerable populations.

    However, the program is under scrutiny from multiple sources including the pharmaceutical and biotech industry, community oncology groups and elements of congress. For organizations with a 340B program, the best defense against these critics is a high functioning compliance program that clearly demonstrates that all required program elements are being met and that the savings from the program are going to the intended purpose.

    Read the full article here